ADIL — Adial Pharmaceuticals Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 65.98 | ||
| Price to Tang. Book | 67.28 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -265.9% | ||
| Return on Equity | -2011.64% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.
Directors
- William Stilley PRE (53)
- Kevin Schuyler VCH (52)
- Joseph Truluck CFO (43)
- Cary Claiborne COO (54)
- Bankole Johnson OTH (61)
- J. Kermit Anderson IND (71)
- Robertson Gilliland IND (41)
- Tony Goodman IND (57)
- James Newman IND (78)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- October 5th, 2017
- Public Since
- July 27th, 2018
- No. of Shareholders
- 85
- No. of Employees
- 5
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,625,890
- Address
- 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE, 22901
- Web
- https://www.adial.com
- Phone
- +1 3026587581
- Auditors
- Marcum LLP
Latest News for ADIL
Upcoming Events for ADIL
Q3 2026 Adial Pharmaceuticals Inc Earnings Release
Q4 2026 Adial Pharmaceuticals Inc Earnings Release
Similar to ADIL
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 19:04 UTC, shares in Adial Pharmaceuticals are trading at $3.92. This share price information is delayed by 15 minutes.
Shares in Adial Pharmaceuticals last closed at $3.92 and the price had moved by -56.31% over the past 365 days. In terms of relative price strength the Adial Pharmaceuticals share price has underperformed the S&P500 Index by -61.08% over the past year.
The overall consensus recommendation for Adial Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAdial Pharmaceuticals does not currently pay a dividend.
Adial Pharmaceuticals does not currently pay a dividend.
Adial Pharmaceuticals does not currently pay a dividend.
To buy shares in Adial Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.92, shares in Adial Pharmaceuticals had a market capitalisation of $10.29m.
Here are the trading details for Adial Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ADIL
Based on an overall assessment of its quality, value and momentum Adial Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Adial Pharmaceuticals is $8.33. That is 112.5% above the last closing price of $3.92.
Analysts covering Adial Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$3.93 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adial Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +133.46%.
As of the last closing price of $3.92, shares in Adial Pharmaceuticals were trading +20.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Adial Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Adial Pharmaceuticals' management team is headed by:
- William Stilley - PRE
- Kevin Schuyler - VCH
- Joseph Truluck - CFO
- Cary Claiborne - COO
- Bankole Johnson - OTH
- J. Kermit Anderson - IND
- Robertson Gilliland - IND
- Tony Goodman - IND
- James Newman - IND